Publications by authors named "F Navid"
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity.
Nat Rev Rheumatol
December 2024
Article Synopsis
- HLA-B*27 significantly increases the risk of developing spondyloarthritis (SpA), which encompasses various forms including axial SpA, peripheral arthritis, and inflammation in several areas of the body.
- The exact mechanism by which HLA-B*27 contributes to SpA is unclear, but three major hypotheses suggest it may promote autoimmune responses, activate harmful immune pathways, and lead to misfolding issues that enhance inflammation and bone formation.
- This review highlights current theories about HLA-B*27's role in SpA, notes recent advancements in research, identifies knowledge gaps, and suggests areas for future investigation.
Article Synopsis
- Desmoid tumors (DT) are rare, aggressive growths that have historically been treated primarily with surgery, but recent trends suggest a shift towards less invasive treatment options.
- A consensus meeting held in Milan in June 2023 aimed to update global guidelines for DT management, bringing together over 90 experts and patient advocates to discuss new strategies and treatments.
- The updated guidelines emphasize the importance of local therapies and include information on the latest medical agents, particularly γ-secretase inhibitors, to ensure informed and effective management of DT in specialized referral centers.
Article Synopsis
- HLA-B27, a significant risk factor for spondyloarthritis (SpA), may involve impaired protein folding and subsequent inflammation pathways, particularly IL-23 induced by endoplasmic reticulum (ER) stress.
- Researchers studied the effect of deleting the CHOP transcription factor, which influences ER stress-related IL-23 production, on gut inflammation in genetically modified rats (HLA-B27-Tg).
- Findings revealed that removing CHOP did not reduce gut inflammation; instead, it increased other pro-inflammatory markers, suggesting that CHOP might actually help mitigate severe gut inflammation linked to HLA-B27.
This study reports the development of an exome capture-based RNA-sequencing assay to detect recurring and novel fusions in hematologic, solid, and central nervous system tumors. The assay used Twist Comprehensive Exome capture with either fresh or formalin-fixed samples and a bioinformatic platform that provides fusion detection, prioritization, and downstream curation. A minimum of 50 million uniquely mapped reads, a consensus read alignment/fusion calling approach using four callers (Arriba, FusionCatcher, STAR-Fusion, and Dragen), and custom software were used to integrate, annotate, and rank the candidate fusion calls.
View Article and Find Full Text PDF